Literature DB >> 19021067

The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.

Mariella D'adda, Moira Micheletti, Monica Drera, Samantha Ferrari, Giuseppe Rossi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19021067     DOI： 10.1080/10428190802353625

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.

Authors:  Luigi Gugliotta; Carlos Besses; Martin Griesshammer; Claire Harrison; Jean-Jacques Kiladjian; Ruth Coll; Jonathan Smith; Brihad Abhyankar; Gunnar Birgegård
Journal:  Haematologica       Date:  2013-12-13       Impact factor: 9.941

Review 2.  Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Authors:  Matjaz Sever; Kate J Newberry; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2014-03-17

3.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.